zum Inhalt springen

Fachbereich Veterinärmedizin


Service-Navigation

    Publikationsdatenbank

    Crystal structures of glycoprotein D of equine alphaherpesviruses reveal potential binding sites to the entry receptor MHC-I (2023)

    Art
    Zeitschriftenartikel / wissenschaftlicher Beitrag
    Autoren
    Kremling, Viviane (WE 5)
    Loll, Bernhard
    Pach, Szymon
    Dahmani, Ismail
    Weise, Christoph
    Wolber, Gerhard
    Chiantia, Salvatore
    Wahl, Markus C.
    Osterrieder, Klaus (WE 5)
    Azab, Walid (WE 5)
    Quelle
    Frontiers in microbiology
    Bandzählung: 14
    Seiten: Artikel 1197120
    ISSN: 1664-302x
    Sprache
    Englisch
    Verweise
    URL (Volltext): https://pubmed.ncbi.nlm.nih.gov/37250020/
    DOI: 10.3389/fmicb.2023.1197120
    Pubmed: 37250020
    Kontakt
    Institut für Virologie

    Robert-von-Ostertag-Str. 7-13
    14163 Berlin
    +49 30 838 51833
    virologie@vetmed.fu-berlin.de

    Abstract / Zusammenfassung

    Cell entry of most alphaherpesviruses is mediated by the binding of glycoprotein D (gD) to different cell surface receptors. Equine herpesvirus type 1 (EHV-1) and EHV-4 gDs interact with equine major histocompatibility complex I (MHC-I) to initiate entry into equine cells. We have characterized the gD-MHC-I interaction by solving the crystal structures of EHV-1 and EHV-4 gDs (gD1, gD4), performing protein-protein docking simulations, surface plasmon resonance (SPR) analysis, and biological assays. The structures of gD1 and gD4 revealed the existence of a common V-set immunoglobulin-like (IgV-like) core comparable to those of other gD homologs. Molecular modeling yielded plausible binding hypotheses and identified key residues (F213 and D261) that are important for virus binding. Altering the key residues resulted in impaired virus growth in cells, which highlights the important role of these residues in the gD-MHC-I interaction. Taken together, our results add to our understanding of the initial herpesvirus-cell interactions and will contribute to the targeted design of antiviral drugs and vaccine development.